Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 13/20 | 0.53 |
| ▸ | FLT4 | P35916 | 13/20 | 0.53 |
| ▸ | KDR | P35968 | 13/20 | 0.53 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411563 | 1.00 | FLT1 (0.53) | FLT1FLT4KDRPTGES2MAOB | |
| SCHEMBL5414126 | 0.91 | FLT1 (0.51) | FLT1FLT4KDRPTGES2HPGD | |
| SCHEMBL5414134 | 0.91 | FLT1 (0.51) | FLT1FLT4KDRPTGES2HPGD | |
| SCHEMBL5418985 | 0.90 | KMT2A (0.49) | FLT1FLT4KDRPTGES2HPGD | |
| SCHEMBL5418975 | 0.90 | KMT2A (0.49) | FLT1FLT4KDRPTGES2HPGD | |
| SCHEMBL4618876 | 0.90 | FLT1 (0.59) | FLT1FLT4KDR | |
| SCHEMBL4618881 | 0.90 | FLT1 (0.59) | FLT1FLT4KDR | |
| SCHEMBL5407436 | 0.89 | PTGES2 (0.54) | FLT1FLT4KDRPTGES2HPGD | |
| SCHEMBL5407443 | 0.89 | PTGES2 (0.54) | FLT1FLT4KDRPTGES2HPGD | |
| SCHEMBL5409699 | 0.88 | PTGES2 (0.51) | FLT1FLT4KDRPTGES2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | FLT1 4126/4885FLT4 4438/4885KDR 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.